EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
Open Access
- 28 May 2018
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 16 (4) , 429-432
Abstract
No abstract availableFunding Information
- Health Technology Assessment Programme
This publication has 7 references indexed in Scilit:
- The Impact of Brexit on Pharmaceuticals and HTAPharmacoEconomics - Open, 2018
- NICE, the NHS, and Cancer DrugsJAMA, 2018
- European drug agency wins victory over drug companies that wanted to withhold data2018
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13BMJ, 2017
- Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overviewJournal of Clinical Epidemiology, 2017
- Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs FundAnnals of Oncology, 2017
- Cancer Drugs Fund 2.0: A Missed Opportunity?PharmacoEconomics, 2016